Skip to content

The Nocebo Effect: a Prospective Study of Informed Consent as a Factor in the Prevalence of SSRI's Side Effects

The Nocebo Effect: a Prospective Study of Informed Consent as a Factor in the Prevalence of SSRI's Side Effects

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01200615
Enrollment
150
Registered
2010-09-13
Start date
2010-10-31
Completion date
2013-10-31
Last updated
2010-09-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression

Keywords

nocebo side-effects SSRI informed consent

Brief summary

In this study we invetigate the influence of the nocebo effect (as part of obtaining informed consent) on the prevalence of side-effects. The study is prospective, focusing on the connection between what the physicians says to the patient about side-effects to the frequency of these side effects during treatment period. We also inquire whether informing the patient about the existence of the nocebo effect influences the extent of phenomena.

Detailed description

In this study the investigators wish to inquire whether the nature of the explenation given to the patient as part of informed consent has an effect on the prevalence of side-effects. The study will take place in the out-patient clinic at the Shalvata Mental health Center. Three arms are included: 1. 50 patients started on SSRI's will be updated about its common side effects 2. 50 patients started on SSRI's will be updated about its common side effects and will receive an explenation on the nocebo effect 3. 50 patients started on SSRI's will receive an explenation on the nocebo effect, but will not be updated about common side-effects. Nonetheless, they will be informed of severe side-effects. Following the prescription of an SSRI the subjects will we enter the follow-up phase of the study. They will attend two follow-up meetings: 3 days after the initiation point and one month after the starting point. During each meeting they will be asked to fill the Antidepressant Side-Effect Checklist (ASEC)and the General Health Questionnaire (GHQ).

Interventions

BEHAVIORALWording of the explenation on side-effects as part of the informed consent.

Subjects will hear different versions of the description of SSRI's side-effects and the nocebo effect.

Sponsors

Shalvata Mental Health Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
PREVENTION
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 66 Years
Healthy volunteers
No

Inclusion criteria

1. age 18-60 2. started on an SSRI

Exclusion criteria

* Psychotic spectrum disorder * Suicidality * Sensitivity to SSRI * Has taken the prescribed SSRI in the past

Design outcomes

Primary

MeasureTime frameDescription
The prevalence of side-effects6 weeksWe are interested in the possible influence of the physicians wording upon recieving informed consend from the patient and the prevalence of side-effects

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026